Primary Focal Segmental Glomerulosclerosis With Proteinuria Therapeutics
1. Filspari patent expiration
Treatment: Treatment of primary immunoglobulin a nephropathy (igan) in adults at risk for disease progression
FILSPARI's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9993461 | TRAVERE | Method for treating disorders associated with glomerular function |
Mar, 2030
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Feb 17, 2028 |
| Orphan Drug Exclusivity(ODE-389) | Feb 17, 2030 |
| Orphan Drug Exclusivity(ODE-493) | Sep 05, 2031 |
Drugs and Companies using SPARSENTAN ingredient
NCE-1 date: 17 February, 2027
Market Authorisation Date: 17 February, 2023
Dosage: TABLET
More Information on Dosage
FILSPARI family patents
